Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).

Author
Li, Susan
Ozguroglu, Mustafa
Luna, Yesenia
Mundle, Suneel
Chi, Kim N.
Fizazi, Karim
Namphuong Tran, Namphuong Tran
Fein, Luis Enrique
Matsubara, Nobuaki
Antolin, Alfredo Rodriguez
Ye, Dingwei
Feyerabend, Susan
Protheroe, Andrew
Sulur, Giri
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/20969
https://doi.org/10.1200/jco.2019.37.7_suppl.141
Collections